PRN – BioTuesdays

Developments

Profound Medical Q4 preliminary revenue beats consensus estimates

Profound Medical (NASDAQ:PROF; TSX:PRN) preliminary revenue for the fourth quarter of 2020 of $3.7-million beat the Street estimate of $2.7-million, despite the pandemic surge. “We believe strong TULSA-PRO adoption and...

January 6, 2021

Markets

Leede Jones Gable starts Profound Medical at buy; PT $36.50 (Canadian)

Leede Jones Gable launched coverage of Profound Medical (TSX:PRN) with a “buy” rating and price target of $36.50 (Canadian). The stock gained $2.96, or 13%, to close at $26.18 on Dec. 21. The firm’s flagship device...

December 22, 2020

Developments

Profound Medical in pact with GE Healthcare to expand access to TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) and GE Healthcare agreed to a non-exclusive, worldwide license that will enable Profound to interface its TULSA-PRO system with certain GE Healthcare MRI scanners. The...

December 21, 2020

Developments

Profound Medical gets FDA humanitarian device exemption approval for Sonalleve

Profound Medical’s (NASDAQ:PROF; TSX:PRN) Sonalleve received FDA humanitarian device exemption (HDE) approval for the treatment of osteoid osteoma. Osteoid osteoma is a non-cancerous bone tumor that occurs most often in...

November 30, 2020

Executive Moves

Profound Medical appoints accomplished financial executive, Murielle Lortie, to board

Profound Medical (NASDAQ:PROF; TSX:PRN) appointed financial executive, Murielle Lortie, as a director, effective immediately. Ms. Lortie is the CFO of Liminal Biosciences, a Nasdaq-listed, clinical-stage...

November 30, 2020

Markets

Jefferies starts Profound Medical at buy; PT $31 (Canadian)

Jefferies launched coverage of Profound Medical (TSX:PRN; NASDAQ:PROF) with a “buy” rating and price target of $31 (Canadian). The stock closed at $18.69 on Sept. 14. Analyst Raj Denhoy writes that Profound’s TULSA-PRO...

September 15, 2020

Markets

Lake Street starts Profound Medical at buy; PT $22 (U.S.)

Lake Street Capital Markets launched coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with a “buy” rating and $22 (U.S.) price target. The stock closed at $15.11 on Sept. 10. Profound develops, manufactures, and...

September 11, 2020

Features

Profound Medical’s TULSA-PRO prostate cancer treatment finds early adopter in Dr. Joseph Busch

As the founder of Atlanta’s renowned Busch Center, Dr. Joseph Busch Jr. brings a 40-year-plus track record in diagnostic radiology and hundreds of international research studies to preventative screening and accurate...

August 11, 2020

Developments Markets

Mayo Clinic listed on TULSA center locator page, indicating Profound Medical’s first sale to a teaching hospital

The Mayo Clinic has just been listed as a new TULSA-PRO site, representing the first sale of the system to a teaching hospital by the technology’s developer, Profound Medical Profound Medical (TSX:PRN; NASDAQ:PROF)...

July 9, 2020

Developments

Analysts see EAU data broadening utility of Profound Medical’s TULSA-PRO

Analysts for Raymond James and Cowen say two posters to be presented at the European Association of Urology (EAU) virtual conference in mid-July enhance the clinical utility of Profound Medical’s (NASDAQ:PROF;...

June 11, 2020

Tag - PRN

Profound Medical Q4 preliminary revenue beats consensus estimates

Leede Jones Gable starts Profound Medical at buy; PT $36.50 (Canadian)

Profound Medical in pact with GE Healthcare to expand access to TULSA-PRO

Profound Medical gets FDA humanitarian device exemption approval for Sonalleve

Profound Medical appoints accomplished financial executive, Murielle Lortie, to board

Jefferies starts Profound Medical at buy; PT $31 (Canadian)

Lake Street starts Profound Medical at buy; PT $22 (U.S.)

Profound Medical’s TULSA-PRO prostate cancer treatment finds early adopter in Dr. Joseph Busch

Mayo Clinic listed on TULSA center locator page, indicating Profound Medical’s first sale to a teaching hospital

Analysts see EAU data broadening utility of Profound Medical’s TULSA-PRO

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter